JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
JCR Pharmaceuticals initiated Phase III trial of JR-142, a long-acting growth hormone for pediatric patients with hormone deficiency, aiming to verify non-inferiority compared to daily Growject over 52 weeks. The trial involves 54 pediatric patients and focuses on efficacy, safety, and growth outcomes.
Highlighted Terms
Related News
JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
JCR Pharmaceuticals initiated Phase III trial of JR-142, a long-acting growth hormone for pediatric patients with hormone deficiency, aiming to verify non-inferiority compared to daily Growject over 52 weeks. The trial involves 54 pediatric patients and focuses on efficacy, safety, and growth outcomes.